298
Participants
Start Date
June 30, 2006
Primary Completion Date
October 31, 2015
Study Completion Date
September 30, 2016
Docetaxel
Chemotherapy agent
Prednisone
steroid in combination with chemotherapy agent
VA Western New York Healthcare System at Buffalo, Buffalo
VA Pittsburgh Health Care System, Pittsburgh
VA Medical Center, Durham, Durham
VA Medical Center, Augusta, Augusta
North Florida/South Georgia Veterans Health System, Gainesville
VA Medical Center, Miami, Miami
James A. Haley Veterans Hospital, Tampa, Tampa
VA Medical Center, Birmingham, Birmingham
VA Medical Center, Memphis, Memphis
G.V. (Sonny) Montgomery VA Medical Center, Jackson, Jackson
VA Medical Center, Lexington, Lexington
VA Ann Arbor Healthcare System, Ann Arbor
John D. Dingell VA Medical Center, Detroit, Detroit
Wlliam S. Middleton Memorial Veterans Hospital, Madison, Madison
VA Medical Center, Minneapolis, Minneapolis
Jesse Brown VAMC (WestSide Division), Chicago
VA Medical Center, Kansas City MO, Kansas City
Overton Brooks VA Medical Center, Shreveport, Shreveport
VA North Texas Health Care System, Dallas, Dallas
Michael E. DeBakey VA Medical Center (152), Houston
VA South Texas Health Care System, San Antonio, San Antonio
VA Salt Lake City Health Care System, Salt Lake City, Salt Lake City
Southern Arizona VA Health Care System, Tucson, Tucson
VA Greater Los Angeles Healthcare System, West LA, West Los Angeles
VA Medical Center, Long Beach, Long Beach
VA San Diego Healthcare System, San Diego, San Diego
VA Medical Center, San Francisco, San Francisco
VA Medical Center, Portland, Portland
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock, North Little Rock
VA Connecticut Health Care System (West Haven), West Haven
New Mexico VA Health Care System, Albuquerque, Albuquerque
Ralph H Johnson VA Medical Center, Charleston, Charleston
VA Medical Center, San Juan, San Juan
Collaborators (1)
Sanofi
INDUSTRY
VA Office of Research and Development
FED